Zhaoke Ophthalmology Narrows Core Loss as Revenue Halves in 2025

Zhaoke Ophthalmology Ltd. ( (HK:6622) ) has issued an announcement.

Zhaoke Ophthalmology reported a sharp decline in revenue to RMB31.97 million for 2025 from RMB69.32 million in 2024, with gross profit falling to RMB16.05 million from RMB51.80 million, reflecting pressure on its commercial operations. The company narrowed its statutory loss to RMB208.98 million from RMB237.49 million and improved its non-HKFRS adjusted loss to RMB202.75 million, while total assets decreased to RMB1.94 billion and equity slipped to RMB1.58 billion, indicating continued investment and cash burn as it pursues growth in the ophthalmology market.

Total liabilities edged up slightly to RMB359.43 million from RMB343.44 million, and total comprehensive income swung further negative to a loss of RMB332.19 million versus RMB156.91 million a year earlier, underscoring ongoing financial strain. Management’s use of non-HKFRS adjusted loss metrics, mainly excluding share-based payment expenses, highlights an effort to present an underlying performance trend as the company balances R&D and commercialization spending against slower top-line growth.

The most recent analyst rating on (HK:6622) stock is a Hold with a HK$3.50 price target. To see the full list of analyst forecasts on Zhaoke Ophthalmology Ltd. stock, see the HK:6622 Stock Forecast page.

More about Zhaoke Ophthalmology Ltd.

Zhaoke Ophthalmology Limited is a Hong Kong-listed company focused on ophthalmic healthcare. It operates in the eye care and ophthalmology sector, developing and commercializing products and treatments for eye diseases in China and broader Asian markets, positioning itself within the specialty pharmaceutical and biotech segment of the healthcare industry.

Average Trading Volume: 779,622

Technical Sentiment Signal: Sell

Current Market Cap: HK$1.61B

For a thorough assessment of 6622 stock, go to TipRanks’ Stock Analysis page.